Jubilant Life gets USFDA nod for epilepsy treatment injection
Drug firm Jubilant Life Sciences has received final approval from the US health regulator for generic Levetiracetam injection, used for treatment of epilepsy, in the American market. Jubilant Life Sciences receives ANDA approval for Levetiracetam Injection USP
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated June 03, 2016 titled "Jubilant Life Sciences receives ANDA approval for Levetiracetam Injection USP". Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
Jubilant Stock Holding Pvt Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE
Jubilant Life gets shareholders nod to raise up to Rs 1,340 crore
The company was seeking shareholders nod through ballot as it intends to issue Indian and/or Foreign Securities for an amount not more than $200 million. Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Jubilant Life Sciences Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Result of Postal Ballot
Jubilant Life Sciences Ltd has submitted to BSE a Copy of the Result of Postal Ballot. SES opposes Jubilant Life warrant issue
Option for deferred part payment of warrant money gives arbitrage opportunity for institutional buyers, says advisory firm
Jubilant Life signs $180 mn outlicensing deal with Checkpoint
"The pact includes an upfront payment of $2 mn and contingent pre-clinical, clinical and regulatory payments including commercials up to $180 mn," JLS added. Jubilant Biosys Enters into Exclusive out - Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors
Jubilant Life Sciences Ltd has informed BSE regarding a Press Release dated May 27, 2016 titled "Jubilant Biosys Enters into Exclusive out - Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors". Jubilant Life Sciences receives ANDA approval for 0.9% Sodium Chloride Injection USP
Jubilant Life Sciences Ltd vide its letter dated May 25, 2016 has informed BSE regarding "Jubilant Life Sciences receives ANDA approval for 0.9% Sodium Chloride Injection USP".